A user shared their 10-month progress using 1mg finasteride daily and micro-needling, noting significant hair regrowth and no side effects. They plan to add oral minoxidil to boost hair density.
The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.
The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
The conversation discusses using a combination of DHT gel, dutasteride, pyrilutamide, and minoxidil to promote beard growth while minimizing hair loss. Users suggest consulting a doctor and considering genetic factors before proceeding.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
A user's progress with treating hair loss by using finasteride (1mg MWF) and minoxidil (5% once daily), occasionally using ketoconazole gel, and dermarolling 1.5mm every two weeks; other users' responses are positive and ask for more information about the treatment regimen.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
A 30-year-old with Norwood 3V hair loss uses finasteride 1.25 mg every other day and Minoxidil (Regaine 5%) twice daily, experiencing no side effects with the current regimen. The front hairline remains unchanged, but the crown appears better in certain lighting.
User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.
The conversation is about trying Keratin Microsphere products for hair loss, specifically SAF 100 Pro, but no noticeable results were observed. The user also mentioned using a Hairclub wand.
The conversation is about how to effectively apply 1mL of a topical hair loss treatment, Pyrilutamide, to cover the entire scalp. One user suggests making a 2.5 mg/mL solution and using 2mL for better coverage.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
A user shared an 8-month update on hair regrowth using HIMS fin/min spray and dermastamping every two weeks, showing significant improvement. Others commented on their own progress and hopes for similar results.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.
The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.